Abstract P2133: Preservation & Vascularization Of Cardiac Extracellular Matrix After Acute Myocardial Infarction

Abstract

Following myocardial infarction (MI), the upregulated matrix metalloproteinases (MMPs) especially MMP-2/9 lead to the degradation of cardiac extracellular matrix (ECM), leading to impaired cardiac function. Therefore, preservation of cardiac ECM by decreasing MMP-2/9 acitivity will increase cardiac function. Meanwhile, vascularization is critical for cardiac ECM as otherwise its structure and composition change over time. In this work, a non-toxic peptide CTTHWGFTLC (CTT) that specifically inhibits MMP-2/9, and a pro-angiogenic basic fibroblast growth factor (bFGF) were used to preserve and vascularize the cardiac ECM. A fast gelling, degradable, and reactive oxygen species (ROS)-scavenging hydrogel was developed to deliver CTT and bFGF to the infarcted hearts. We evaluated the efficacy of the delivery system in preserving and vascularizing cardiac ECM, and improving cardiac function. The combination of CTT and bFGF synergistically promoted tube formation of HUVECs compared to the treatment with CTT or bFGF (**p<0.01). Interestingly, both CTT and bFGF inhibited myofibroblast differentiation of cardiac fibroblasts. The combination of CTT and bFGF further significantly decreased the differentiation. After 28 days of implantation of the CTT/bFGF/Gel, the wall thickness was significantly increased compared to the CTT/Gel, bFGF/Gel, Gel only and MI. The released CTT and bFGF preserved cardiac ECM, decreased cardiac fibrosis, and stimulated angiogenesis in the infarcted area, leading to a significant increase of cardiac function.